January 26, 2018 / 9:08 AM / a year ago

BRIEF-GlaxoSmithkline Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma

Jan 26 (Reuters) - GlaxoSmithkline Plc:

* GSK’S RELVAR ELLIPTA - POSITIVE CHMP OPINION

* GSK ANNOUNCES CHMP POSITIVE OPINION FOR LABELLING UPDATE TO RELVAR ELLIPTA IN PATIENTS WITH ASTHMA

* ‍NO NEW SAFETY SIGNALS WERE IDENTIFIED AND ADVERSE EVENT DATA WERE CONSISTENT WITH KNOWN SAFETY PROFILE FOR FF/VI ESTABLISHED IN PATIENTS WITH ASTHMA​

* ‍FINAL DECISION IS ANTICIPATED TOWARDS END OF Q1 OF 2018 ​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below